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Abstract The genomes of many species have now been
completely sequenced including human and mouse. Great
progress has been made in understanding the complex ge-
netics that underlie diabetes and obesity in human popula-
tions. One of the current challenges is the functional
identification and characterization of the genes within loci
that are being mapped. There are many approaches to this
problem and this review outlines the valuable role that the
mouse can play. We outline the mouse resources that are
available to the research community, including knockouts
with conditional potential for every gene, and the efforts of
the International Mouse Phenotyping Consortium to attach
phenotype information to these genes. We also briefly con-
sider the potential of TALEN technology to tailor-make new
mouse models of specific mutations discovered in humans.
Finally, we consider the recent progress in characterizing the
GWAS genes FTO, TCF7L2, CDKAL1, and SLC30A8 in
engineered mouse models.
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Introduction
Type 2 diabetes clearly has a genetic component and disease
susceptibility reflects an interaction between multiple genes,
environmental challenges, and age. The strongest challenge is
obesity and, for example, European males with a Body Mass
Index (BMI) >35 kg/m2 and a waist circumference of >102 cm
are 22 times more likely to develop diabetes than males with
low BMI [1]. Over the past 5 years there has been great
progress in identifying human loci associated with diabetes
and obesity and many other diseases and traits. Human Ge-
nome wide association studies (GWAS) have so far associated
over 50 genes with type 2 diabetes (reviewed in [2]). These
studies identify single nucleotide polymorphisms (SNPs) that
are associated with specific diseases. The identified SNPs may
not be directly responsible for the disease but may be in linkage
disequilibrium with functional variants that affect a causative
gene, likely within the region. Identification of the underlying
causative gene is therefore necessary and there are a variety of
approaches that may achieve this aim, including the use of
mouse models. Often these genes were not previously associ-
ated with a disease and in some cases may be of unknown
function. Identification of the underlying gene and its function
and the pathway and mechanisms it affects, offers the hope of
finding targets for therapeutic intervention, regardless of the
size of effect of the original mapped locus. A combination of
association and expression studies applied to the KLF14 gene
locus in humans also illustrates the potential for discovering
novel networks from single starting genes [3••].
This review summarizes new mouse resources and
emerging technologies. Further, we highlight recent prog-
ress in the utilization of mouse models for the study of
human type 2 diabetes loci and which illustrate the potential
of the mouse to human (and back again) approach.
Mouse Models for Diabetes Genes
Diabetes is a complex disease involving many organ sys-
tems and multiple signaling pathways; therefore it is neces-
sary to investigate its causes and effects in vivo. Mice have
been shown to be a strong model for many human diseases
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including diabetes. Accepting the obvious differences of
size and shape and some particular metabolic differences
(such as high HDL-C) the mouse is very similar physiolog-
ically, anatomically, and genetically to humans. Mice also
breed quickly, have a short accelerated lifespan, can be kept
in defined conditions, and maintained relatively cheaply.
Standardized protocols for mouse phenotyping are avail-
able to help laboratories characterize their models in a
comparable way (EMPReSS http://empress.har.mrc.ac.uk/,
IMPReSS http://www.mousephenotype.org/impress/,
EUMORPHIA http://www.eumorphia.org/). Precise diag-
nostic criteria that are used to identify the disease in man
are not used in the mouse; instead wild-type and mutant
mice (age- and sex-matched individuals, which are ideally
littermates) are compared with one another. Similar diag-
nostic tests as those used in human patients have been
established in the mouse [4]. This allows phenotyping
results to be at least partly comparative between mouse
models and human leading to stronger translatable results.
The use of random mutagenesis and exploitation of spon-
taneous mutations to develop models has been used for
many years [5]. However, over the past 20 years or so
extensive tools to manipulate the mouse genome have been
developed allowing specific mutations to be introduced [6].
New Mouse Resources
There are a number of resources available to the research
community to provide mice for their studies. The Federation
of International Mouse Resources (FIMRe) is a collaborat-
ing group of mouse repository and resource centers world-
wide (Table 1) that archive and provide strains of mice as
cryopreserved embryos and gametes, ES cell lines, and live
breeding stock (http://www.fimre.org/).
Following on from the completion of the mouse genome
sequence, that in principal identified every gene in the genome,
the International Knock-out Mouse Consortium (IKMC) was
developed to systematically generate null mutant embryonic
stem (ES) cells that provide “knockout first” alleles that can
then be converted into conditional alleles (alleles that are null
only from specific time points and/or specific tissues) for every
protein coding gene (20,000 plus genes) in the mouse genome
([7•] Table 2). These resources are readily available to the
research community [8]. Exploiting the knockout mouse re-
source the International Mouse Phenotyping Consortium
(IMPC, http://www.mousephenotype.org/) has been estab-
lished and funded to create mouse lines from each targeted
ES cell and to determine the phenotype of the resulting mutant
mice [9, 10]. Through high-throughput phenotyping of each
line, including glucose and body composition traits, using
pipelines already established by pilot programs such as
EUMODIC (http://www.eumodic.eu/), functional information
can be attached to every gene in the mouse genome [10]. This
should provide novel genes and models for translational re-
search for human diseases including type 2 diabetes.
Mouse Models for Specific Human Mutations–New
Technology
Transcription activator like effector nucleases (TALENs) were
first reported in 2010 [11]. They are very similar to Zinc finger
nucleases (ZFNs), binding to a particular DNA sequence and
then causing a double stranded DNA break, the cell then
utilizing homologous recombination that allows a homolo-
gous donor sequence to be introduced, and used as a template
for DNA repair thus integrating a desired sequence (carrying a
tailored modification) into the genome, or in the absence of a
donor sequence error prone non-homologous end-joining that
may lead to deletions or insertions that may result in a null
allele [12–14]. These manipulations can be carried out in
zygotes and substantially speeds up the process of making a
tailored mutant mouse. This is a very efficient process but is
limited by the repertoire of ZFNs and the potential for off
target mutations. However, TALEN technology may be more
flexible and have reduced off target events. TALENs are made
of DNA binding modules that each recognizes a single nucle-
otide and thus it is possible to assemble a protein that recog-
nizes a sequence of choice (reviewed [15]). This protein can
Table 1 Members of the Feder-
ation of International Mouse
Resources (FIMRe)
Member Link
The Jackson Laboratory (TJL) http://www.jax.org/
Mouse Mutant Resource Regional Centres (MMRRC) http://www.mmrrc.org/
Mouse Models of Human Cancer Consortium (MMHCC) http://emice.nci.nih.gov/
Canadian Mouse Consortium (CMC) http://www.mousecanada.ca/
Canadian Mouse Mutant Repository (CMMR) http://www.cmmr.ca/
European Mouse Mutant Archive (EMMA) http://www.emmanet.org/
RIKEN BioResource Center (RBRC) http://www.brc.riken.jp/lab/animal/en/
Center for Animal Resources and Development (CARD) http://card.medic.kumamoto-u.ac.jp/
Australian Phenomics Network (APN) http://www.australianphenomics.org.a/
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then be coupled with a nuclease or another modifying protein
for specific delivery to a unique site in the genome (reviewed
[16]). In the last year TALENs have successfully been used to
engineer site specific mutations in yeast, zebra fish, rats,
plants, and human pluripotent stem cells [17]. The ability to
introduce precisely targeted changes at high efficiency has
many applications, including introducing human mutations
into mouse genes quickly and precisely, and may also find
utility in the manipulation of single exon genes where there is
a risk of disturbing important flanking sequences by conven-
tional targeting methods, especially if a conditional allele is
required. These technologies hold the promise of targeted
gene correction in human induced pluripotent stem cells, as
has been recently demonstrated for correcting a biallelic point
mutation in α-1-antitrypsin, which in man causes a deficiency
which leads to emphysema [18].
Genes in Man and Mouse
To illustrate the application of mouse genetics in going
“from mice to humans” we will now consider 4 genes from
human diabetes GWAS examined in recent studies; FTO,
TCF7L2, CDKAL1, and SLC30A8 (Fig. 1), all of which had
Table 2 Members of the International Knockout Mouse Consortium (IKMC)
Member Role
International Knockout Mouse Consortium
(IKMC)
Enables the IKMC database to be searched for a gene of interest by gene symbols, gene IDs or
genome location. Provides information on availability of knockout attempts and other
resources. Incorporates information from all the partners and provides a “one stop shop” for
information on knockouts for your gene of interest.
http://www.knockoutmouse.org/
NIH Knockout Mouse Project (KOMP) Incorporates KOMP-CSD and KOMP-Regeneron, Inc.
http://www.nih.gov/science/models/mouse/
knockout/
KOMP-CSD use promoterless and promoter-driven targeting cassettes to make a 'Knockout-first
allele' and produce frame shift mutations of a ‘critical’ exon.
KOMP-Regeneron Velocogene constructs generate complete null alleles that delete the entire
protein coding sequence of the target gene.
Provides central database resource through the Knockout Mouse Project Data Coordination
Centre (KOMP DCC).
KOMP Repository to archive, maintain and distribute KOMP products.
The European Conditional Mouse Mutagenesis
Program (EUCOMM)
Uses conditional gene targeting and trapping approaches to generate 12,000 conditional mutants
as ES cells.
www.eucomm.org/
North American Conditional Mouse
Mutagenesis project (NorCOMM)
Utilizes a combination of gene trap random mutagenesis and systematic high-throughput tar-
geting of remaining un-trapped genes.
http://www.norcomm.org/index.htm
Texas A&M Institute for Genomic Medicine
(TIGM)
A huge resource of over 350,000 gene trap C57BL/6N
http://www.tigm.org/
ES cell lines for more than 13,000 mouse genes.
In addition holds 270,000 sequence-tagged 129/SvEvBrd gene trap embryonic stem cell clones.
Fig. 1 From mice to humans. Mouse models allow specific genes to
be manipulated and tested for their effects on metabolism and physi-
ology. These models can also be challenged in a number of ways to
reveal phenotypes, for example by feeding a high fat diet. These
models can provide tissues for physiological analysis and RNA,
DNA, and protein for molecular analysis of any tissue at any stage of
development or challenge. Suitable models can also be used for testing
compounds that may target specific genes and pathways, in the search
for therapeutic opportunities. The underling genes for testing may
come from GWAS studies; they may also be identified in mouse
mutagenesis programs as giving rise to relevant disease traits. Patients
carrying mutations and polymorphisms in genes inform the genetics
and allow cross correlation of the metabolic and physiological effects
in models, directing the use of models and testing their validity
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not previously been considered as prominent candidates for
diabetes research until uncovered by GWAS.
FTO
In 2007 a T2D GWAS identified a strong signal at
rs9939609, in intron 1 of the FTO gene. This association
was due to an increased body mass index (BMI), and al-
though the SNP was intronic, the gene where it was found
was of unknown function, and was a close neighbor to
RPGRIP1L (formerly FTM) [19, 20]. Individuals homozy-
gous for the risk allele weigh on average 3 kg more than
those individuals without it, and since the identification of
this SNP several groups have worked on this region to
understand the cause of the increased BMI, and several
different mouse models have been generated.
A preexisting model with a large 1.6 Mb deletion of 6
genes including Fto had severe developmental defects with
homozygote mice dying during gestation [21]. This model
although interesting was not specific enough to understand the
function of Fto. A knockout mouse was generated by Fischer
and colleagues. Homozygous knockout mice are lean, with a
mild insulin sensitivity improvement, but they are also growth
retarded [22]. Another knockout from Gao et al. had a similar
phenotype, and this group also generated a nervous system
specific knockout using a general neuronal Cre recombinase
(driven by the nestin gene promoter) to delete a floxed exon 3
in nestin expressing cells and obtained a similar phenotype
[23]. They concluded that Fto functions in the central nervous
system to regulate postnatal growth [23]. Screening the ENU
DNA archive (male mice carrying ENU induced point muta-
tions stored as tissues, DNA, and frozen sperm for IVF) at
MRC Harwell led to the identification of a dominant point
mutation in Fto (FTOI367F) in exon 6 of the gene. Mice
homozygous for this mutation are lean and do not show
perinatal lethality or an effect on body length [24]. Finally
Church and colleagues also generated a mouse which condi-
tionally overexpresses the Fto gene from the Rosa26 locus
using the CAGGs promoter (chicken b-actin promoter) [25].
Mice carrying extra copies of the gene have a dose dependent
increase in body weight due to increased adipose tissue mass
and adipocyte size. These overexpression mice are hyper-
phagic and when fed a high fat diet have an increased glucose
tolerance and increased fasting insulin.
These mouse models suggest that FTO plays a role in
control of body weight and composition. Therefore the
identified SNP could affect FTO function or expression.
Although FTO is not a direct candidate for T2D, it does
increase the risk for becoming overweight. This can be seen
in the overexpression mouse model, as when these animals
are fed a high fat diet they have a decreased glucose toler-
ance. These mice will therefore be a useful model for
obesity and T2D translational studies.
FTO is an excellent example of how by using mouse
models it has been possible to validate a GWAS identified
gene of unknown function associated to obesity and T2D.
This approach can therefore be applied to other GWAS loci,
to identify the underlying genes [26].
TCF7L2
The TCF7L2 locus was initially mapped as a suggestive
locus with linkage to chromosome 10 in an Icelandic popula-
tion and then confirmed in a second study [27, 28]. Subse-
quent GWAS have shown TCF7L2 to be a consistent strong
signal in many studies and exhibits one of the largest effects
(odds ratio per allele about 1.37) to date (see in particular [20,
29, 30], and reviewed [31]). Data from individuals carrying
risk alleles indicated lowered insulin secretion [32]. Work
with isolated islets and insulin secreting cell lines has shown
that loss of TCF7L2 leads to decreased insulin secretion in
response to glucose and incretins [33–35].
What have mouse models contributed to the understand-
ing of this gene that had already been validated in vitro? A
constitutive knockout of this gene leads to lethality shortly
after birth due to intestinal defects and thus precludes an
analysis of glucose homeostasis in these animals [36]. Savic
et al. (2011) have carried out 3 types of experiment using
mice [37••]. In one they used human bacterial artificial
chromosomes (BACs, large segments of DNA usually in
the 100–150 kb range) engineered to express blue LacZ to
test enhancer driven expression in embryos (visualizing the
blue staining) and demonstrated that the genomic interval
encompassing the diabetes associated SNPs drive expres-
sion in relevant tissue such as intestine and pancreas (al-
though surprisingly not in adult islets), in contrast to BACs
outside of the region. Further an engineered deletion of the
associated region from the expressing BAC abolished ex-
pression, thus pointing to the presence of control sequences
within this region, and affecting the expression of Tcf7l2
(see also a follow up study by Savic et al. [37••, 38]). In the
second experiment they made a Tcf7l2 knockout using zinc
finger nucleases to cause a frameshift in exon 11. As ob-
served for the constitutive knockout, homozygous null mice
died soon after birth. However heterozygous null mice
showed improved glucose tolerance and reduced insulin
on a standard and high fat diet. Finally, Savic et al. (2011)
took a human BAC with a mouse cDNA recombineered into
the TCF7L2 translation start site and generated a series of
mice overexpressing Tcf7l2. These mice exhibited glucose
intolerance on a high fat diet. Thus these experiments dem-
onstrate that the associated SNPs are in regulatory elements
(although perhaps not for adult islets at least in the context
of a randomly integrated transgenic BAC) and that manip-
ulating Tcf7l2 expression modulates glucose tolerance, low
expression improving and higher expression impairing
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glucose tolerance. Another group using a knockout first
allele from the IKMC confirmed the perinatal homozygous
lethality of null mice and improved glucose tolerance in
heterozygous mice [39]. Significantly, Gaulton et al.
(2009) have shown that the chromatin of the TCF7L2
intronic variant is in an islet-specific open conformation
[40]. Further, that the diabetes associated rs7903146 T allele
chromatin is in a more open conformation than the C allele.
An open conformation indicates active gene regulatory ele-
ments that may affect transcriptional rates, promoter usage,
and differential splicing. Reporter assays demonstrated in-
creased enhancer activity of the T allele compared with the
C allele in beta cell lines [40]. These data are consistent with
increased expression from the risk allele in islets leading to
increased diabetes risk and is consistent with the above
mouse studies.
In the studies described above all of the manipulations
are present in the germline and then all tissues. In order to
address the question whether selective deletion of Tcf7l2 in
pancreas impairs or improves glucose homeostasis and in-
sulin secretion Xavier et al. carried out a conditional knock-
out using Pdx1 promoter Cre recombinase and a floxed exon
one [41••]. Mice carrying both alleles specifically and ho-
mozygously deleted exon 1 during early endocrine pancreas
development and were compared with mice carrying the Cre
only. When challenged with an intraperitoneal glucose bolus
these mice showed age dependent glucose intolerance by
20 weeks of age. In an oral glucose tolerance test, impair-
ment was detectable from 12 weeks of age; in this test the
incretin response (peptides secreted from the gut that ampli-
fy insulin secretion by the beta cell) contributes to glucose
tolerance. Isolated islets showed impaired glucose stimulat-
ed insulin secretion and GLP-1 (an incretin) response. These
pancreas specific knockout phenotypes are consistent with
the in vitro human and mouse islet and cell line siRNA-
mediated silencing experiments. However, they contrast the
heterozygous global constitutive mouse knockouts and
overexpression experiments and the active chromatin
experiments in human islets that were described earlier. It
is clear that Tcf7l2 is expressed in multiple tissues and
therefore in the other models glucose tolerance may be
affected by changes in other tissues as those manipulations
were not tissue specific, unlike the Xavier et al. experiment
where there is deletion in islets alone. Although Pdx1 driven
Cre will delete in other islet endocrine cells, no difference
was observed in circulating glucagon or GLP-1 levels
strongly implicating beta cells. Another possible explana-
tion for the discrepancies is that there is a high degree of
tissue specific alternative splicing of the TCF7L2 gene
[42–45]. In these various experiments the Tcf7l2 gene is
manipulated in different ways and each may alter the tissue
specific splicing of the gene and in the case of the cDNA
overexpression experiment only 1 isoform is represented. It
will be interesting to evaluate the different mRNA isoforms
expressed in each of these situations.
The mouse in vivo experiments clearly confirm the im-
portance of Tcf7l2 in glucose homeostasis but reveal a
complex picture where more than 1 tissue may be relevant.
The complete loss of the gene in islet cells definitively
impairs insulin secretion and incretin response. Further tis-
sue specific manipulation of expression will be very inter-
esting and will contribute to our understanding of gene and
tissue specific function.
CDKAL1
CDK5 regulatory subunit associated protein 1-like 1
(CDKAL1) is homologous to CDK5RAP1, an inhibitor of
cyclin-dependent kinase CDK5, which can transduce gluco-
toxicity signals in pancreatic β-cells. CDKAL1 has been
recently associated to T2D by several GWASs [20, 29,
46–48] and replicated in many other studies, it has also been
associated with low birth weight in those carrying the risk
allele [49].
Despite the initial, homology observation the biochemi-
cal function of CDKAL1 was unclear, however, further
bioinformatic sequence analysis, and functional assays iden-
tified CDKAL1 as the first eukaryotic member of the meth-
ylthiotransferase family (MTTase) to be found so far [50].
Using a mouse knockout Wei et al. were able to demonstrate
that Cdkal1 specifically modifies the tRNA for lysine from
t6A (N6-threonyl carbamoyl adenosine) at position 37 to
ms2t6A (2-methylthio-N6-threonyl carbamoyl adenosine),
a modification specific to this tRNA and essential to prevent
codon misreading [51••]. Cdkal1 gene-trap knockout mice
have impaired β-cell function, showing impaired glucose
stimulated first-phase insulin release in vitro [52]. Wei et al.
[51••] used a β-cell specific knockout of Cdkal1, finding
islet hypertrophy, decreased insulin secretion, and impaired
blood glucose control. They also observed that misreading
of a Lys codon in proinsulin occurred, resulting in a reduc-
tion of glucose stimulated proinsulin synthesis. This reduced
translation accuracy, causes the synthesis of abnormal insu-
lin, which triggered ER stress in β-cells. The adverse effects
of this mutation were exacerbated by high fat diet feeding.
These studies demonstrate a clear link between this gene
within a GWAS locus and insulin secretory defects that may
at least partly explain the association with type 2 diabetes.
SLC30A8 (ZnT-8)
Solute carrier family 30, member 8 (SLC30A8) encodes a
ZnT8 zinc transporter, expressed highly in the pancreas, and
regulates zinc efflux [53]. It has been associated with fasting
glucose levels and T2D risk in several GWAS studies
[30, 47, 54]. Recently Kanoni and colleagues conducted
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a large-scale gene-diet interaction meta-analysis. They
identified a nominally significant interaction between total
zinc intake and the SLC30A8 rs11558471 variant on fasting
glucose levels. This suggests an inverse association between
total zinc intake and fasting glucose in individuals carrying the
glucose-raising A allele [55].
Several groups have generated global knockout ZnT8
mice, which have been a useful tool for investigating its
link with T2D. Two groups have looked in parallel at
an exon 1 knockout mouse line maintained as separate
colonies and both found effects on zinc accumulation by
β-cells, glucose intolerance and insulin secretion that
were diet, age, and genetic background dependent
[56–58]. Interestingly insulin secretion in isolated islets
was either preserved or enhanced [56–58]. This model
is useful as it may parallel disease in humans where for
example, obesity may result in increased demand on β-
cells for insulin that leads to a chain of events resulting
in impairment of insulin secretion, and because of pre-
disposing gene variants, like ZnT8, diabetes [56–58].
Another group has made an exon 3 knockout finding
similar effects on zinc metabolism and normal glucose
tolerance; it would be interesting to examine the effect
of high fat diets on these mice [56]. In contrast to the
exon 1 knockouts islets from these mice showed im-
paired glucose stimulated insulin secretion that may
again reflect age, diet, and genetic background effects
[56]. The ZnT8 gene is expressed in α-cells (secreting
the counter-regulatory hormone glucagon) and a number
of other tissues in addition to β-cells. Conditional
knockout mice have been used to specifically knockout
the gene in α or β-cells alone to address the contribu-
tion of each cell type. Again using the exon 1 floxed
allele, mice were crossed with rat insulin promoter Cre
recombinase line (to delete exon 1 in β-cells), or a
glucagon promoter Cre (to delete in α cells), and the
result was that the β-cell knockout mice showed many
of the original features of the global knockout including
glucose intolerance and a reduction in glucose stimulat-
ed insulin secretion, whilst in contrast, α cell deletion
showed no abnormalities in plasma glucagon levels or
glucose homeostasis [59•]. These experiments demon-
strate that loss of function of this gene in the β-cell,
rather than in α cells, gives rise to the diabetes associ-
ation of this gene. In another study a β-cell knockout
was compared with whole body knockout mice that had
been fed a high fat diet. The β-cell knockout mice
developed glucose intolerance as described before, but
remained similar in weight to control mice. In contrast,
whole body deletion leads to obesity and severe insulin
resistance [60]. These experiments suggest both β-cell
specific and non-β-cell tissue specific effects involving
the ZnT8 gene and type 2 diabetes risk [60].
Conclusions
The mouse has proven to be a useful model system for the
exploration of the genetics of diabetes and has a role to play in
translating the results of GWAS (loci that contain genes that
are relevant to human disease susceptibility), alongside other
approaches. As the specific examples described above dem-
onstrate, these experiments can provide valuable insights that
are relevant to human studies. This technological approach
can be used to identify underlying culprit genes within loci
where this is unknown and also to eliminate candidate genes
and so functionally “fine map” an association signal. As with
any model system there are going to be differences when
comparing to heterogeneous human populations and that is
whymouse genetics needs to be part of an integrated approach
that includes human patient studies where possible. Projects
such as IKMC and IMPC provide a resource of knockout mice
that means these approaches are accessible to any group with
access to a mouse facility. The phenotyping of knockout genes
and the availability of that data in public databases will un-
doubtedly reveal new targets in the field of diabetes that can be
tested for a role in patients. New technologies are adding to
our ability to manipulate genes in the mouse and indeed to
contemplate human gene therapies.
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